UK markets close in 57 minutes

Galapagos NV (0JXZ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
55.28-0.37 (-0.67%)
As of 07:04AM GMT. Market open.
Full screen
Previous close55.65
Open55.22
BidN/A x N/A
AskN/A x N/A
Day's range55.22 - 55.28
52-week range32.26 - 55.28
Volume115
Avg. volume21,615
Market capN/A
Beta (5Y monthly)0.03
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

    Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation. Andrew Dickinson is Gilead's Chief Financial Officer (CFO) and replaces Daniel O’Day, Gilead’s Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024. Mr. Dickinson jo

  • Globe Newswire

    Galapagos announces full year 2023 results and outlook for 2024

    Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, i

  • GlobeNewswire

    Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

    - First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRASG12C- FMC-376 has the potential to transform patient outcomes with its ability to overcome both innate and acquired resistance mechanisms and brain metastases BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformation